Dynavax Technologies Co. (NASDAQ:DVAX) saw some unusual options trading activity on Monday. Traders acquired 2,440 put options on the stock. This is an increase of 1,352% compared to the typical volume of 168 put options.

In related news, insider Robert Coffman sold 7,500 shares of the firm’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP David Louis Johnson sold 3,092 shares of the firm’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total transaction of $57,511.20. Following the transaction, the vice president now directly owns 7,780 shares of the company’s stock, valued at $144,708. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Several large investors have recently modified their holdings of the business. Vident Investment Advisory LLC grew its stake in shares of Dynavax Technologies by 3.1% in the 3rd quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 4,553 shares in the last quarter. First Republic Investment Management Inc. purchased a new position in shares of Dynavax Technologies in the 3rd quarter worth $2,414,000. Crawford Lake Capital Management LLC bought a new stake in shares of Dynavax Technologies in the 3rd quarter worth about $1,481,000. California State Teachers Retirement System lifted its holdings in shares of Dynavax Technologies by 12.0% in the 3rd quarter. California State Teachers Retirement System now owns 97,417 shares of the biopharmaceutical company’s stock worth $2,094,000 after acquiring an additional 10,412 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Dynavax Technologies by 29.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 235,310 shares of the biopharmaceutical company’s stock worth $5,060,000 after acquiring an additional 54,149 shares during the last quarter. 70.54% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies (NASDAQ DVAX) opened at $15.75 on Friday. Dynavax Technologies has a 52 week low of $3.70 and a 52 week high of $24.45. The company has a market cap of $954.39, a price-to-earnings ratio of -8.04 and a beta of 1.31.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.28 million. During the same period last year, the company posted ($0.90) EPS. The business’s revenue was down 68.8% on a year-over-year basis. analysts anticipate that Dynavax Technologies will post -1.72 EPS for the current year.

Several equities analysts recently weighed in on DVAX shares. Cowen reaffirmed a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. BidaskClub cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Cantor Fitzgerald started coverage on shares of Dynavax Technologies in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 price objective for the company. Finally, Zacks Investment Research cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $25.17.

COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies Target of Unusually High Options Trading (DVAX)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/dynavax-technologies-target-of-unusually-high-options-trading-dvax/1805089.html.

About Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.